receptor antagonist
Primary endpoint data
IMPLANT 4 Q4 2019
EU MAA filing planned
late 2019
FDA feedback expected
in 2019 for potential US
IMPLANT 3 Initiation 2H
2019
Exclusive
Worldwide
Oral GnRH
receptor antagonist
52W extension data
1H 2019
EoP2 meeting
completed
Commencing Phase 3
Q1 2019
Phase 3 PRIMROSE
1 & 2 Enrolling
24W Primary Endpoint
Data Q4 2019-Q1 2020
NDA targeted end of 2020
Exclusive
Worldwide
(ex-Asia)
receptor antagonist
EU Phase 2a
PROLONG
Interim Efficacy
1H 2019
Exclusive
Worldwide